No widely accepted protocol or guideline existsfor monitoring ototoxicity in patients who take powerful and potentially cochleotoxic and/or vestibulotoxic agents. Many physicians in other specialties who prescribe these drugs do not understand the important role of otolaryngologists and audiologists in pretreatment counseling and evaluation and the needfor f ollow-up assessm ents of their pati ents ' auditoryfun ction. Based on our combin ed experience of more than 50 years, we have developed a uniform yetflexible approach to monitoring cochlear and vestibularfuncti on in thesepat ients. We discuss the mechanisms ofototoxic agents, risk factorsfor ototoxicity, the need f or ongoing communication among the various disciplin es, and the methods and timing ofmonitoring.
Introduction
No universally accepted protocol or standard of care exists for monitoring aural function in patie nts with serious infections or cancer who take potentially ototoxic agents. 1-4 A rigid standard would certainly not be practical in light of the complex ity of the issues invo lved and the wide variety of potentially ototoxic agents. Some basic protocols have been disc ussed,"? but textbooks on sensorineural hearing loss do not offer a complete guideline for preventing and monitorin g ototoxicity.
We believe it would be helpful to codify an understanding of what it is that we wish to accomplish in such cases. Based on our combined 50 years of clinical experience in a variety of institutions and clinic al settings, we have developed a basic protocol for monitoring ototoxicity (figure) . In this article , we describe our recommendations, with empha sis on the mechanisms of ototoxic agents, risk factors for ototoxicity, the importance of interdisciplinary comm unication , and the specific methods and timing of monitoring.
Ototoxic drugs
Physicians typica lly strive to select the most cost-effective and least toxic medication available, but in some circumstances the standard of care dictates the use of powerful, potentially toxic drugs (table 1) . Although physician s attempt to achieve a drug concentration only high enough to produce an adequate clinical effect and therapeutic result , ototoxicity can occur even in patients who take an appropriate dose and in those who have normal peak and trough levels. In fact, ototoxicity can occur after only a single dose. Initia lly, agents that are toxic to the cochlea destroy outer hair cells in the basal turn of the cochlea , which cause s a high-frequency sensorineural hearing loss. Later, as the effec ts of these agents progre ss apically through the cochlea, a flat sensorineural hearing loss occurs. Aminoglycosi de antibiotics concentra te in the perilymph and endolymph . Some (amikacin, dihydros treptomycin, and kanamycin) are primarily and/or initially cochleotoxic, while others (streptomycin and gentamicin) destroy vestibular hair cells before cochle ar hair cells. Most of these drugs, when given for long periods of time or when their serum concentrations are high, most often cause a loss of both cochlear and vestibular hair cells. Oftentimes, the destruction of hair cells continues for weeks after the treatment is discontinued. Some agent s (aspirin and quinine) have a temporary effect on the cochlea, while others cause a permanent hearing loss. Loop diuretics can cause reversible hearing loss at lower dosages, but not in all patients."Whenever possible , the physician should counsel the patient about the potential for ototoxicity and other risks, as well as the benefit s of treatment, prior to the initiation of therapy .
Risk factors for ototoxicity
The key to preve nting ototoxicity is early detection. An important component of early detection is an awareness 
Interdisciplinary communication
A coordinated and coopera tive effort sho u ld be m aintain ed amo ng the patient' s primary care and/or specialist phys icia n, the otolaryngolog ist, and the audiologist so that coch leo-or vestibulotoxicity can be detected early . It is particul arly essential that the otolaryngo logis t and the audiologist be made aware of the name of the drug, the dosage, any changes in the med ication regimen, the manner of the drug's absorption and excretion , the status of the patient ' s kidn ey and liver function, and the patient' s risk factors for ototoxic ity.
Con versely, the otolaryngologist and/or audiolog ist should relay to the patient ' s treating physicia n the res ults of ototoxicity monitoring tests and any changes in the patient' s otolog ic status. The audiolog ist migh t be the firs t memb er of the management team to recognize subtle changes in the patient' s clinical symptoms or abnormalities in cochlear and vestibul ar function. Input from the audiologis t is critical.
of the risk factors that can predispose patients to druginduced ototoxicity:
• previous use of an ototoxic age nt • simultaneo us exposure to multiple ototoxic agen ts • adminis tration of an ototoxic age nt for more than 14 days • administration of multi ple courses of an ototox ic drug • adminis tration of an aminoglycoside in combi nation with a loop diure tic • high seru m levels of an ototox ic agent (a conse quence of a failure to monitor peak and tro ugh levels) • pre-existing sensorineural hearing loss with evi dence of outer-hair-cell loss • impaired ren al function (apropos to age nts that are excreted by the kidney) and compromised hepatic func tion (apro pos to age nts tha t are excre ted by the liver) • age (the elderly are at higher risk) • genetic factors (e.g., hypersensitivity to an ototoxic drug)
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Methods of monitoring
The otola ryngo logist should ensure that the audio logist is familiar with the parameters of peak and trough levels. Peak levels are usually measured 1 hour following the administration of a drug, and trough levels are measured 15 minutes pr ior to the administration of the next dose. With some exceptions, peak and trough levels are generally meas ured once a week. For patient s who have abnormal kidney or liver function, these levels might be measured daily . Kidney and liver function shou ld be assessed before treatm ent is initiated . For patients whose rate of exc retio n is decreased, the physician migh t consider lowering the dosage, although there is no abso lute clinical evidence that doing so will prevent ototoxic ity. Ototoxicity can also occ ur in patients whose ren al and hepatic function is norm al.
In addition, monitoring of blood pH , electrolyte, and oxyge n saturat ion levels mig ht be appropriate for some patient s. Eva luation of the drug's prot ein-binding effec ts might also be advisab le.
When mo nitori ng for ototoxici ty, we cannot rely on 
Timing of monitoring tests
Before the initiation of treatment, eac h patie nt shou ld undergo a baseli ne eva luation with the tests previously mentioned. The same battery of tests shou ld be conducted at every subseq uent visit ( figure) . In addition to the base line eva luation, testing should be performed within 24 hour s before the initiation of trea tme nt, once a week Many patients who req uire monitoring for ototoxic ity are extremely ill, and any vestibulotoxic effects and changes in hearing that they experience are often masked by their overall poor medical stat us. Furthermore, transporting such patients to the audiology unit might not be possible, and patient cooperation might be limited. Therefore, a flexib le and compassionate approach to mon itoring these patients is necessary. Even if bedside testing is the only available method of monitoring these patients, it is certainly preferable to no testing at all. audiometric testing alone. By the time audiometric testing reveals a hearing loss , it might be too late to reverse it. We recommend that the following tests be performed routinely at every visit:
• conventional audiometry (a significant change is defi ned as a IS-dB shift at one or more frequencies?or a 20-dB shift at one freq uency") • dete rmi nation of the speech discrimination score • high-fre quency audiometry (to 18 kHz) if the patient is able to undergo this test • aco ustic imp edance testi ng • aco ustic imm ittance testin g • auditory brainstem-evoked response testing for very young patients and for patien ts who are cri tica lly ill or confined in some way • otoacoustic emissions testing • elec tronystagmography when app licable • cli nica l symptoms checklist review Monitoring the robustness of otoacoustic emissions and noting changes in the response over time might provide an early indication of hair-cell damage. If otoacoustic emissions are not elicited during the baseline evaluation, repeat testing might not be necessary.
Electronystagmography is necessary when a drug is bei ng used that is known to have a vestibulotox ic effect so that changes in vestibular function can be detected early . Although cessation of the drug at the first sig n of vestibular irritab ility might not necessarily change the progression of the vestibular abnormality, early detection might spare the cochlear function. However, drug discont inuation can lead to imm ed iate or delayed symp toms, including tinnitus, ver tigo, and hearing loss.
A rev iew of the clin ical symptoms checklist should be made duri ng every visit. Th e otolaryngologist or audiologist sho uld ask the patient if he or she has experienced tinnitus, vertigo, or a change in hearing sta tus, and the patient sho uld be instructed to immediately report any onset of or cha nge in these symptoms.
Many drugs can have an effect on testing resu lts, even though they are not necessarily ototoxic themselves (table 2): By either depressing or stimulating the central nervous system, some medications elicit hyper-or hypoactive responses. Tranquilizers cause central nervous system depression, alco hol and anticonvulsants produce cerebellar dysfunction, and antihypertensives can cause orthostatic hypotension and subsequent dizziness. " Therefore, when possible, and with the treating physician's approval, the patient sho uld discontinue taking any such agent prior to undergoing monitoring tests . It is especially important that the effects of these substances be taken into acco unt when testi ng vestibular function by electronystag mograp hy. patient receives the highest standard of care. Adherence to these guidelines will afford us the opportunity to maximize our ability to prevent ototoxicity in patients who take powerful lifesaving medication s.
during the treatment course, immediately prior to the initiation of each new treatment cycle, and at the completion of treatment. Also, post-treatment follow-up assessments should take place at 2 weeks, 4 weeks, 12 weeks, and 6 month s. The timing of an immediate or delayed adverse drug reaction cannot be predicted. The time of onset varies according to the specific drug that is used and the length of treatment. There fore, the timing of monitoring visits might need to be adjusted. Decisions as to making such adjustments should take into consider ation the clini cal experience of the physician, the audiologist, and the institution as a whole .
When a monitoring test detect s a change from a baseline value, the change must be confirmed by repeat testing . Once a change has been reconfirmed, the patient should be monitored daily until the paramet er in question has stabilized.
As is the case with very ill adults, monitoring children can be challenging. The protocol used to monitor older children can be modeled on the paradigm used for adults, but for very young children it might be necessary to rely only on objective tests, such as otoacoustic emissions testing, tympanomet ry, and auditory brainstem-evoked response testing . Also, when evaluating a newborn or infant, it is necessary to take into considerat ion any drugs that might have been administered to the mother and that might have passed through the placenta to the patient in utero.
Management of ototoxicity
At the first indic ation that an ototoxic effect has occurred, the physician has several options:
• a reduc tion in the amount of the dose • a change in the timing of the dosage schedule • a temporary discontinuation of therapy so that the ear can "rest" • a switch to a less ototoxic drug If the treating physician does switch the patient to a different drug, a new baseline must be established to ensure proper monitoring. In some cases, the physician will not be able to change the drug regimen because of the intensity or severity of the patient' s illness. When ototoxicity occurs, referral for vestibular and/or aural rehabilitation is indicated, particularly for patients who experience permanent hearing loss.
Although our protocol allows for some flexibility, we recommend that otolaryngologi sts and audiologists follow it as closely as possible in order to develop a cohesive and consistent approach to monitoring patients at risk. Good communication among the patient , the audiologist, and all involved physicians is imperative so that the
